Zhao Yunhe, Huang Jiaming, Liu Tianyu, He Shanyang, Shang Chunliang, Guo Luyan, Du Qiqiao, Yao Shuzhong
Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen UniversityZhongshan Second Road 58, Guangzhou 510080, Guangdong, P. R. China.
Am J Transl Res. 2018 Mar 15;10(3):684-695. eCollection 2018.
The expression level and clinical significances of long non-coding RNAs (LncRNAs) are presently unknown in the early-stage cervical cancer (CC). This study was aimed to explore the expression signatures of lncRNAs between normal and cervix carcinoma tissues and the prognostic value of LncRNAs in early-stage CC patients.
The patients diagnosed with FIGO stage I-IIb CC of the First Affiliated Hospital of Sun Yat-sen University between January 1st 2006 and December 31st 2009 were retrospectively reviewed. Molecular microarray was conducted to identify differentially expression profiles of LncRNAs. In situ hybridization was applied for detection of candidate lncRNAs in cervical tissues.
A total of 2574 upregulated lncRNAs and 3270 downregulated lncRNAs with significantly differential expression (≥2.0-fold) were identified. Among the differentially expressed lncRNAs, RP11-396F22.1 expression was one of the most significantly overexpressed in the CC tissues compared to nomal cervical tissues (P<0.001). hybridization confirmed RP11-396F22.1 expression was highly expressed in cancerous tissues. The results of Scratch and Transwell test showed that the migration ability decreased remarkably in transfected group (P<0.001). Moreover, the coding gene cpne8 was significantly upregulated by RP11-396F22.1 knockdown (P=0.035).
These findings demonstrate that LncRNA RP11-396F22.1 might be a potent biomarker for CC progression.
目前，长链非编码RNA（LncRNAs）在早期宫颈癌（CC）中的表达水平及临床意义尚不清楚。本研究旨在探索正常宫颈组织与宫颈癌组织之间LncRNAs的表达特征，以及LncRNAs在早期CC患者中的预后价值。
回顾性分析2006年1月1日至2009年12月31日在中山大学附属第一医院诊断为FIGO I-IIb期CC的患者。进行分子微阵列以鉴定LncRNAs的差异表达谱。应用原位杂交检测宫颈组织中的候选LncRNAs。
共鉴定出2574个上调的LncRNAs和3270个下调的LncRNAs，其表达差异显著（≥2.0倍）。在差异表达的LncRNAs中，与正常宫颈组织相比，RP11-396F22.1在CC组织中的表达是最显著上调的之一（P<0.001）。原位杂交证实RP11-396F22.1在癌组织中高表达。划痕实验和Transwell实验结果显示，转染组的迁移能力显著降低（P<0.001）。此外，通过敲低RP11-396F22.1，编码基因cpne8显著上调（P=0.035）。
这些发现表明LncRNA RP11-396F22.1可能是CC进展的一个潜在生物标志物。
